ClinicalTrials.gg
RecruitingNCT06061562TAPASUpdated Jan 17, 2024

Down Syndrome, Physical Activity and Sleep Apnea

An observational study in Down Syndrome, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Down Syndrome with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Down Syndrome · France.

Planned enrollment
18th of 23
50 · median 100
Started
2024
with 3 others
Observational
23 of 40
6 open now
Primary completion
2026-12
later than 3 of 11 live
Registered
28th of 40
by date
Lead sponsor
3 of 40
University Hospital, Grenoble

Among the 40 studies in Down Syndrome with a site in France, this one is the 18th largest by planned enrollment of the 23 observational ones that give a count, is one of 4 that started in 2024, is one of 23 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 28th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

12 of the 40 studies in Down Syndrome with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Down Syndrome with a site in France, or all of them as a file.
02

Study summary

To realize a sleep phenotyping in a population with Down syndrome, its determinants, and the consequences of these disorders, with a specific focus on sleep apnea syndrome.

Read the detailed description

Sleep disorders are widely observed in the Down's syndrome population, due to a number of risk factors, and can become established in early childhood. Diagnosis of sleep disorders in Down's syndrome is difficult and often delayed, which can contribute to poor health in children with Down's syndrome. Phenotyping sleep characteristics in this Down Syndrome population will enable early identification of the consequences of these disorders, with a specific focus on sleep apnea syndrome, whose origin is multisystemic.

03

Conditions studied

  • Down Syndrome

Keywords

  • Down syndrome
  • sleep disorders
  • Apnea
  • physical activity
  • neurocognition
  • autonomic nervous system
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Down syndrome is associated with numerous clinical expressions. The most frequent are deficits in cognitive development, autonomic nervous system dysfunctions, cardiovascular dysfunctions, and osteoarticular specificities. Taken together, these clinical features can lead to a sedentary and overweight lifestyle, directly responsible for the onset of early fatigue and effort limitation. Numerous co-morbidities are also reported, such as the presence of sleep apnea syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Total autosomal trisomy caused by the presence of a third copy (partial or total) of chromosome 21

Exclusion criteria

Exclusion Criteria:

  • People with abnormal electrocardiographic tracings,
  • Existence of heart failure or cardiovascular disease, as determined by any abnormalities in cardiovascular adaptations to exercise.
  • Existence of a declared or uncontrolled progressive disease.
  • pregnant or breast-feeding women.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • DS group

    A cohort of participants (child, teenager, or adult), with or without sleep disorders

06

What researchers measure

Primary outcomes

  1. phenotyping of sleep in a population with Down's syndrome, its determinants, and the consequences of these disorders, with a specific focus on sleep apnea syndrome, whose origin is multisystemic

    Diagnosis of Sleep Apnea Syndrome using calculation of apnea hypopnea index (AHI)\>15 events/h

    Time frame: Visite 2: 2 nights

Secondary outcomes

  1. Sleep-disordered breathing associated with dysautonomia

    Polysomnography

    Time frame: Visite 2: 1 night

  2. Sleep-disordered breathing associated with dysautonomia

    Heart rate (beat per min) recording using a cardiofrequency meter to measure the RR interval (in milliseconds); measured over 3 nights max in an ecological environment

    Time frame: Visite 2: up to 3 nights

  3. Sleep-disordered breathing associated with dysautonomia

    The variables used to assess the autonomic profile will be obtained by calculating LF and LF(low and high frequency in ms² and normalized units) spectral variations and the LF/HF ratio

    Time frame: Visite 2: up to 3 nights

  4. Sleep-disordered breathing associated with specific abnormalities of the biological work-up

    Biological disturbances will be assessed by differences in thyroid function, and other biological variables (NFS, lipid and hormone levels, iron levels) in comparison with standards. This biological assessment is obtained by blood sampling.

    Time frame: Visite 1: the morning before the physical activity

  5. Sleep-disordered breathing associated with a specific cranial structure

    The existence of cranial anatomical variations, in particular anomalies specific to the oral sphere (modification of the gonia angle (in degrees), and prognatism (in cm)) will be investigated by cephalometry.

    Time frame: Day 0

  6. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by questionnaires (scores).

    Time frame: Day 0 and visite 1

  7. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by actimetry (min per day)

    Time frame: From inclusion to last visit of the patient: up to 90 days

  8. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by anthropometric variables (Weight (kg)

    Time frame: Day 0 and visite 1: 1 time

  9. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by Height (m)

    Time frame: Day 0 and visite 1: 1 time

  10. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by BMI (kg/m²)

    Time frame: Day 0 and visite 1: 1 time

  11. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by determinants of physical fitness (measurement of strength (Newton)

    Time frame: Visite 1: up to 1 hour

  12. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by flexibility (cm)

    Time frame: Visite 1: up to 1 hour

  13. Sleep-disordered breathing associated with inadequate physical activity

    Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by balance variables (seconds).

    Time frame: Visite 1: up to 1 hour

  14. Sleep-disordered breathing associated with inadequate physical activity

    Effort response (% chronotropic response) will also be calculated to complete the autonomic profile.

    Time frame: Visite 1: up to 1 hour

  15. Sleep-disordered breathing associated with specific neurobehavioral disorders

    A neurobehavioral profile assessment will be carried out using several tests, in order to verify the possible impact of TdS on cognitive function: * Intelligence quotient (Wechsler scale), if not previously performed (score) * Stroop task (inhibitory control) (score) * Reaction time using a light device (seconds) * Ability to perform a double cognitive-motor task, (score) * BRIEF questionnaire (to explore executive function) (score) * ADHD rating scale (to explore signs of attention deficit/hyperactivity disorder). (score)

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 35 months is above that.

Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Sep 29, 2023
StartActual
Jan 11, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06061562
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Jan 11, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 17, 2024

Study contacts

Veronique BRICOUT
Contact
VBricout@chu-grenoble.fr
0476767226
Sébastien BAILLIEUL
principal investigator · University Grenoble Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion